Keep up with our comprehensive coverage of administrative and legislative activity and what it means for industry, plans, providers, and patients.
Moving certain Part B drugs to Part D, a proposal being evaluated by the Trump administration, would have disparate financial impacts on patients.
The Department of Health and Human Services is seeking public input on a variety of proposals related to drug costs, providing stakeholders with an unprecedented opportunity to shape the administration's drug pricing policies.
President Trump is expected to announce a drug pricing plan in the coming weeks; signals from the White House indicate potential alignment around several priority policies.
Increasingly, states are taking steps to control prescription drug spending and prices.
The shift from volume to value has played a significant role in shaping current payer behavior in the oncology space.
New research from Avalere finds that most health plans are covering at least one of the two biosimilar products currently on the market.
Avalere experts review proposed drug pricing policies from each stakeholder's perspective across the industry and the implications each might carry.